XERS News and Press, Xeris Pharmaceuticals Inc. From 12/22/20

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an exclusive distribution a...

During the second week of December, several penny stocks have rallied in a big way. This is likely due to several key factors that investors should know about. The overarching theme in the market right now and for the past six months has been COVID. It has affected both penny stocks and...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion for Xeris Pharmaceuticals' (XERS) Ogluo (glucagon) recommending Ogluo for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The Europe...

Positive CHMP Opinion based on data from a multi-center, randomized Phase 3 trial Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectab...

Last year, I was neutral about the Xeris Pharmaceuticals story; but a lot of positives have happened this year. There's a marketed product, a steadily rising revenue stream, a platform with potential, and George Soros recently purchased a 5% stake. Xeris looks a lot more enticing ...

Image source: The Motley Fool. Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) Q3 2020 Earnings Call Nov 9, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Xeris Pharmaceuticals, Inc. (XERS) Q3 2020 Earnings Call Transcr...

Xeris Pharmaceuticals, Inc. (XERS) Q3 2020 Earnings Conference Call November 9, 2020 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations and Corporate Communication Paul Edick - Chairman and Chief Executive Officer Barry Deutsch - Chief Financial Officer ...

Xeris Pharmaceuticals (XERS): Q3 GAAP EPS of -$0.35 beats by $0.19.Revenue of $9.4M beats by $4.92M.Shares +4.6% PM.Press Release For further details see: Xeris Pharmaceuticals EPS beats by $0.19, beats on revenue

Gvoke® net sales grew 370% quarter over quarter to $9.4 million driven by launch of Gvoke HypoPen® Company to host a conference call and webcast today at 8:30 a.m. ET Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging ...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its third quarter 2020...